KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

The role of sulbactam-durlobactam in treating carbapenem-resistant Acinetobacter infections.

Matteo Bassetti, Daniele Roberto Giacobbe, Nadia Castaldo, Antonio Vena

Curr Opin Infect Dis 37(6) 547-553

PMID39259710
PMCID-
DOI10.1097/QCO.0000000000001059
发表日期2024-09-11
摘要

摘要

PURPOSE OF REVIEW: Infections caused by multidrug-resistant Acinetobacter baumannii present a significant global health challenge. Available treatment options are limited and frequently constrained by unfavourable safety and pharmacokinetic profiles. Sulbactam-durlobactam is a novel β-lactamase inhibitors combination specifically developed to target A. baumannii , including carbapenem-resistant strains. The purpose of this review is to assess the current evidence supporting the role of sulbactam-durlobactam in the management of A. baumannii infections. RECENT FINDINGS: We summarize the available evidence regarding the pharmacokinetic and pharmacodynamic profiles of sulbactam-durlobactam from key in-vitro and in-vivo studies. Additionally, efficacy results from the Phase III randomized controlled trial and real-world data on sulbactam-durlobactam's use against severe A. baumannii infections are also discussed. SUMMARY: Sulbactam-durlobactam is a promising addition to the treatment options for carbapenem-resistant A. baumannii infections. Ongoing research and vigilance are essential to monitor the development of in-vivo resistance, assess effectiveness across diverse patient populations, and explore potential synergistic combinations with other antimicrobials. Careful stewardship and comprehensive clinician education will be crucial to optimizing the clinical use of sulbactam-durlobactam.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。